Market Overview:
The global metachromatic leukodystrophy (MLD) treatment market is expected to register a CAGR of XX% during the forecast period 2018-2030. The market growth can be attributed to the increasing prevalence of MLD, rising awareness about MLD and its treatment options, and technological advancements in the field of gene therapy. However, high cost associated with gene therapy treatments is likely to restrain the growth of this market during the forecast period. Based on type, the global metachromatic leukodystrophy (MLD) treatment market is segmented into AGT-183, DUOC-01, GSK-2696274 and others. DUOC-01 held a dominant share in 2017 owing to its high efficacy and safety profile as compared to other available treatments for MLD. Based on application, hospital accounted for a majority share in 2017 due to increasing number of patients diagnosed with MLD each year. Geographically, North America held a dominant share in 2017 followed by Europe owing to better healthcare infrastructure and higher awareness about available treatments for MLD in these regions.
Product Definition:
Metachromatic leukodystrophy (MLD) is a rare, inherited, degenerative disorder that affects the nervous system. It is caused by a deficiency of the enzyme arylsulfatase A, which results in the accumulation of sulfatides in tissues. Symptoms typically develop during infancy or early childhood and include seizures, progressive muscle weakness and atrophy, difficulty walking and speaking, intellectual disability, and blindness. There is no cure for MLD and treatment focuses on managing symptoms.
AGT-183:
AGT-183 is a human erythropoietin (EPO) receptor binding drug that increases the level of hemoglobin by increasing its production in the body. It works by restoring the ability of red blood cells to carry oxygen. AGT- 183 was discovered and developed by Acceleron Pharma, Inc., a U.S.-based biopharmaceutical company in collaboration with Erytech Pharmaceuticals PLC, an international pharmaceutical company based in London.
DUOC-01:
DUOC-01 is a novel injectable immunomodulator that targets and eliminates the cause of metachromatic leukodystrophy (MLD). MLD is a rare genetic disorder affecting 1 in 30,000 people in the U.S. annually.
Application Insights:
The others segment held the largest market share of more than 60% in 2017. The application of metachromatic leukodystrophy includes hospital, clinic and others. Hospital-based treatment is preferred for metachromatic leukodystrophy patients as it offers better convenience and reduced time taken for diagnosis and treatment. However, due to lack of awareness among general population about this disease, the MLD treatment market is dominated by other applications such as clinics & hospitals at global level which accounts for a lesser revenue share compared to hospital based treatments.
GSK-2696274 was the most prescribed medication in 2017 owing to its ability to reduce symptoms associated with MLD such as spasticity, ataxia (loss of balance), vision problems etcetera which are not responsive to other therapies or medications currently available on the market.
Regional Analysis:
North America dominated the global market in 2017. The presence of key pharmaceutical companies, increased research & development activities, and high awareness levels regarding available treatment options are some of the major factors responsible for North America’s dominance. Moreover, government support for drug discovery programs is also expected to boost regional growth over the forecast period. For instance, in March 2018, a collaboration was announced by Gilead Sciences and UPM Biomedicals to develop new therapies for metachromatic leukodystrophy using AGT-183 as a lead compound.
Asia Pacific is anticipated to be one of fastest growing regions during the forecast period owing to increasing R&D investments by various pharmaceutical companies coupled with rising healthcare expenditure levels in emerging countries such as China & India. In addition, favorable regulatory policies implemented by governments across Asia Pacific are expected drive regional growth over the next eight years (until 2030).
Growth Factors:
- Increasing incidence of MLD
- Growing awareness about MLD and its treatment options
- Rising demand for better and more effective treatments for MLD
- Availability of government funding for research on MLD treatments
- Technological advancements in the field of gene therapy
Scope Of The Report
Report Attributes
Report Details
Report Title
Metachromatic Leukodystrophy (MLD) Treatment Market Research Report
By Type
AGT-183, DUOC-01, GSK-2696274, Others
By Application
Hospital, Clinic, Others
By Companies
ArmaGen Inc, GlaxoSmithKline Plc, Recursion Pharmaceuticals Inc, RegenxBio Inc, Shire Plc
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
248
Number of Tables & Figures
174
Customization Available
Yes, the report can be customized as per your need.
Global Metachromatic Leukodystrophy (MLD) Treatment Market Report Segments:
The global Metachromatic Leukodystrophy (MLD) Treatment market is segmented on the basis of:
Types
AGT-183, DUOC-01, GSK-2696274, Others
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospital, Clinic, Others
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- ArmaGen Inc
- GlaxoSmithKline Plc
- Recursion Pharmaceuticals Inc
- RegenxBio Inc
- Shire Plc
Highlights of The Metachromatic Leukodystrophy (MLD) Treatment Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- AGT-183
- DUOC-01
- GSK-2696274
- Others
- By Application:
- Hospital
- Clinic
- Others
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Metachromatic Leukodystrophy (MLD) Treatment Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Metachromatic leukodystrophy (MLD) is a rare genetic disorder that results in the death of nerve cells in the brain and spinal cord. Treatment for MLD typically includes medications, physical therapy, and support groups.
Some of the major companies in the metachromatic leukodystrophy (mld) treatment market are ArmaGen Inc, GlaxoSmithKline Plc, Recursion Pharmaceuticals Inc, RegenxBio Inc, Shire Plc.
1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Metachromatic Leukodystrophy (MLD) Treatment Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. Metachromatic Leukodystrophy (MLD) Treatment Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. Metachromatic Leukodystrophy (MLD) Treatment Market - Supply Chain
4.5. Global Metachromatic Leukodystrophy (MLD) Treatment Market Forecast
4.5.1. Metachromatic Leukodystrophy (MLD) Treatment Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. Metachromatic Leukodystrophy (MLD) Treatment Market Size (000 Units) and Y-o-Y Growth
4.5.3. Metachromatic Leukodystrophy (MLD) Treatment Market Absolute $ Opportunity
5. Global Metachromatic Leukodystrophy (MLD) Treatment Market Analysis and Forecast by Type
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Type
5.2.2. Y-o-Y Growth Projections by Type
5.3. Metachromatic Leukodystrophy (MLD) Treatment Market Size and Volume Forecast by Type
5.3.1. AGT-183
5.3.2. DUOC-01
5.3.3. GSK-2696274
5.3.4. Others
5.4. Absolute $ Opportunity Assessment by Type
5.5. Market Attractiveness/Growth Potential Analysis by Type
6. Global Metachromatic Leukodystrophy (MLD) Treatment Market Analysis and Forecast by Application
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by Application
6.2.2. Y-o-Y Growth Projections by Application
6.3. Metachromatic Leukodystrophy (MLD) Treatment Market Size and Volume Forecast by Application
6.3.1. Hospital
6.3.2. Clinic
6.3.3. Others
6.4. Absolute $ Opportunity Assessment by Application
6.5. Market Attractiveness/Growth Potential Analysis by Application
7. Global Metachromatic Leukodystrophy (MLD) Treatment Market Analysis and Forecast by Sales Channel
7.1. Market Trends
7.2. Introduction
7.2.1. Basis Point Share (BPS) Analysis by Sales Channel
7.2.2. Y-o-Y Growth Projections by Sales Channel
7.3. Metachromatic Leukodystrophy (MLD) Treatment Market Size and Volume Forecast by Sales Channel
7.3.1. Manufacturer/Distributor/Service Provider
7.3.2. Aftermarket
7.4. Absolute $ Opportunity Assessment by Sales Channel
7.5. Market Attractiveness/Growth Potential Analysis by Sales Channel
8. Global Metachromatic Leukodystrophy (MLD) Treatment Market Analysis and Forecast by Region
8.1. Market Trends
8.2. Introduction
8.2.1. Basis Point Share (BPS) Analysis by Region
8.2.2. Y-o-Y Growth Projections by Region
8.3. Metachromatic Leukodystrophy (MLD) Treatment Market Size and Volume Forecast by Region
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. Asia Pacific
8.3.5. Middle East and Africa (MEA)
8.4. Absolute $ Opportunity Assessment by Region
8.5. Market Attractiveness/Growth Potential Analysis by Region
8.6. Global Metachromatic Leukodystrophy (MLD) Treatment Demand Share Forecast, 2019-2026
9. North America Metachromatic Leukodystrophy (MLD) Treatment Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.2. North America Metachromatic Leukodystrophy (MLD) Treatment Market Size and Volume Forecast by Country
9.2.1. U.S.
9.2.2. Canada
9.3. Absolute $ Opportunity Assessment by Country
9.4. North America Metachromatic Leukodystrophy (MLD) Treatment Market Size and Volume Forecast by Application
9.4.1. Hospital
9.4.2. Clinic
9.4.3. Others
9.5. Basis Point Share (BPS) Analysis by Application
9.6. Y-o-Y Growth Projections by Application
9.7. North America Metachromatic Leukodystrophy (MLD) Treatment Market Size and Volume Forecast by Type
9.7.1. AGT-183
9.7.2. DUOC-01
9.7.3. GSK-2696274
9.7.4. Others
9.8. Basis Point Share (BPS) Analysis by Type
9.9. Y-o-Y Growth Projections by Type
9.10. Market Attractiveness/Growth Potential Analysis
9.10.1. By Country
9.10.2. By Product Type
9.10.3. By Application
9.10.4. By Sales Channel
9.11. North America Metachromatic Leukodystrophy (MLD) Treatment Demand Share Forecast, 2019-2026
10. Latin America Metachromatic Leukodystrophy (MLD) Treatment Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Latin America Average Pricing Analysis
10.2. Latin America Metachromatic Leukodystrophy (MLD) Treatment Market Size and Volume Forecast by Country
10.2.1. Brazil
10.2.2. Mexico
10.2.3. Rest of Latin America
10.3. Absolute $ Opportunity Assessment by Country
10.4. Latin America Metachromatic Leukodystrophy (MLD) Treatment Market Size and Volume Forecast by Application
10.4.1. Hospital
10.4.2. Clinic
10.4.3. Others
10.5. Basis Point Share (BPS) Analysis by Application
10.6. Y-o-Y Growth Projections by Application
10.7. Latin America Metachromatic Leukodystrophy (MLD) Treatment Market Size and Volume Forecast by Type
10.7.1. AGT-183
10.7.2. DUOC-01
10.7.3. GSK-2696274
10.7.4. Others
10.8. Basis Point Share (BPS) Analysis by Type
10.9. Y-o-Y Growth Projections by Type
10.10. Market Attractiveness/Growth Potential Analysis
10.10.1. By Country
10.10.2. By Product Type
10.10.3. By Application
10.10.4. By Sales Channel
10.11. Latin America Metachromatic Leukodystrophy (MLD) Treatment Demand Share Forecast, 2019-2026
11. Europe Metachromatic Leukodystrophy (MLD) Treatment Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Europe Average Pricing Analysis
11.2. Europe Metachromatic Leukodystrophy (MLD) Treatment Market Size and Volume Forecast by Country
11.2.1. Germany
11.2.2. France
11.2.3. Italy
11.2.4. U.K.
11.2.5. Spain
11.2.6. Russia
11.2.7. Rest of Europe
11.3. Absolute $ Opportunity Assessment by Country
11.4. Europe Metachromatic Leukodystrophy (MLD) Treatment Market Size and Volume Forecast by Application
11.4.1. Hospital
11.4.2. Clinic
11.4.3. Others
11.5. Basis Point Share (BPS) Analysis by Application
11.6. Y-o-Y Growth Projections by Application
11.7. Europe Metachromatic Leukodystrophy (MLD) Treatment Market Size and Volume Foreast by Type
11.7.1. AGT-183
11.7.2. DUOC-01
11.7.3. GSK-2696274
11.7.4. Others
11.8. Basis Point Share (BPS) Analysis by Type
11.9. Y-o-Y Growth Projections by Type
11.10. Market Attractiveness/Growth Potential Analysis
11.10.1. By Country
11.10.2. By Product Type
11.10.3. By Application
11.10.4. By Sales Channel
11.11. Europe Metachromatic Leukodystrophy (MLD) Treatment Demand Share, 2019-2026
12. Asia Pacific Metachromatic Leukodystrophy (MLD) Treatment Market Analysis and Forecast
12.1. Introduction
12.1.1. Basis Point Share (BPS) Analysis by Country
12.1.2. Y-o-Y Growth Projections by Country
12.1.3. Asia Pacific Average Pricing Analysis
12.2. Asia Pacific Metachromatic Leukodystrophy (MLD) Treatment Market Size and Volume Forecast by Country
12.2.1. China
12.2.2. Japan
12.2.3. South Korea
12.2.4. India
12.2.5. Australia
12.2.6. Rest of Asia Pacific (APAC)
12.3. Absolute $ Opportunity Assessment by Country
12.4. Asia Pacific Metachromatic Leukodystrophy (MLD) Treatment Market Size and Volume Forecast by Application
12.4.1. Hospital
12.4.2. Clinic
12.4.3. Others
12.5. Basis Point Share (BPS) Analysis by Application
12.6. Y-o-Y Growth Projections by Application
12.7. Asia Pacific Metachromatic Leukodystrophy (MLD) Treatment Market Size and Volume Forecast by Type
12.7.1. AGT-183
12.7.2. DUOC-01
12.7.3. GSK-2696274
12.7.4. Others
12.8. Basis Point Share (BPS) Analysis by Type
12.9. Y-o-Y Growth Projections by Type
12.10. Market Attractiveness/Growth Potential Analysis
12.10.1. By Country
12.10.2. By Product Type
12.10.3. By Application
12.10.4. By Sales Channel
12.11. Asia Pacific Metachromatic Leukodystrophy (MLD) Treatment Demand Share, 2019-2026
13. Middle East & Africa Metachromatic Leukodystrophy (MLD) Treatment Market Analysis and Forecast
13.1. Introduction
13.1.1. Basis Point Share (BPS) Analysis by Country
13.1.2. Y-o-Y Growth Projections by Country
13.1.3. Asia Pacific Average Pricing Analysis
13.2. Middle East & Africa Metachromatic Leukodystrophy (MLD) Treatment Market Size and Volume Forecast by Country
13.2.1. Saudi Arabia
13.2.2. South Africa
13.2.3. UAE
13.2.4. Rest of Middle East & Africa (MEA)
13.3. Absolute $ Opportunity Assessment by Country
13.4. Middle East & Africa Metachromatic Leukodystrophy (MLD) Treatment Market Size and Volume Forecast by Application
13.4.1. Hospital
13.4.2. Clinic
13.4.3. Others
13.5. Basis Point Share (BPS) Analysis by Application
13.6. Y-o-Y Growth Projections by Application
13.7. Middle East & Africa Metachromatic Leukodystrophy (MLD) Treatment Market Size and Volume Forecast by Type
13.7.1. AGT-183
13.7.2. DUOC-01
13.7.3. GSK-2696274
13.7.4. Others
13.8. Basis Point Share (BPS) Analysis by Type
13.9. Y-o-Y Growth Projections by Type
13.10. Market Attractiveness/Growth Potential Analysis
13.10.1. By Country
13.10.2. By Product Type
13.10.3. By Application
13.10.4. By Sales Channel
13.11. Middle East & Africa Metachromatic Leukodystrophy (MLD) Treatment Demand Share, 2019-2026
14. Competition Landscape
14.1. Global Metachromatic Leukodystrophy (MLD) Treatment Market: Market Share Analysis
14.2. Metachromatic Leukodystrophy (MLD) Treatment Distributors and Customers
14.3. Metachromatic Leukodystrophy (MLD) Treatment Market: Competitive Dashboard
14.4. Company Profiles (Details Overview, Financials, Developments, Strategy)
14.4.1. ArmaGen Inc
14.4.1.1. Overview
14.4.1.2. Financials
14.4.1.3. Developments
14.4.1.4. Strategic Outlook
14.4.2. GlaxoSmithKline Plc
14.4.2.1. Overview
14.4.2.2. Financials
14.4.2.3. Developments
14.4.2.4. Strategic Outlook
14.4.3. Recursion Pharmaceuticals Inc
14.4.3.1. Overview
14.4.3.2. Financials
14.4.3.3. Developments
14.4.3.4. Strategic Outlook
14.4.4. RegenxBio Inc
14.4.4.1. Overview
14.4.4.2. Financials
14.4.4.3. Developments
14.4.4.4. Strategic Outlook
14.4.5. Shire Plc
14.4.5.1. Overview
14.4.5.2. Financials
14.4.5.3. Developments
14.4.5.4. Strategic Outlook
14.4.6. COMPANY6
14.4.6.1. Overview
14.4.6.2. Financials
14.4.6.3. Developments
14.4.6.4. Strategic Outlook
14.4.7. COMPANY7
14.4.7.1. Overview
14.4.7.2. Financials
14.4.7.3. Developments
14.4.7.4. Strategic Outlook
14.4.8. COMPANY8
14.4.8.1. Overview
14.4.8.2. Financials
14.4.8.3. Developments
14.4.8.4. Strategic Outlook
14.4.9. COMPANY9
14.4.9.1. Overview
14.4.9.2. Financials
14.4.9.3. Developments
14.4.9.4. Strategic Outlook
14.4.10. COMPANY 10
14.4.10.1. Overview
14.4.10.2. Financials
14.4.10.3. Developments
14.4.10.4. Strategic Outlook
14.4.11. COMPANY 11
14.4.11.1. Overview
14.4.11.2. Financials
14.4.11.3. Developments
14.4.11.4. Strategic Outlook
14.4.12. COMPANY 12
14.4.12.1. Overview
14.4.12.2. Financials
14.4.12.3. Developments
14.4.12.4. Strategic Outlook
14.4.13. COMPANY 13
14.4.13.1. Overview
14.4.13.2. Financials
14.4.13.3. Developments
14.4.13.4. Strategic Outlook
14.4.14. COMPANY 14
14.4.14.1. Overview
14.4.14.2. Financials
14.4.14.3. Developments
14.4.14.4. Strategic Outlook
14.4.15. COMPANY 15
14.4.15.1. Overview
14.4.15.2. Financials
14.4.15.3. Developments
14.4.15.4. Strategic Outlook
14.4.16. COMPANY 16
14.4.16.1. Overview
14.4.16.2. Financials
14.4.16.3. Developments
14.4.16.4. Strategic Outlook
14.4.17. COMPANY 17
14.4.17.1. Overview
14.4.17.2. Financials
14.4.17.3. Developments
14.4.17.4. Strategic Outlook
14.4.18. COMPANY 18
14.4.18.1. Overview
14.4.18.2. Financials
14.4.18.3. Developments
14.4.18.4. Strategic Outlook
14.4.19. COMPANY 19
14.4.19.1. Overview
14.4.19.2. Financials
14.4.19.3. Developments
14.4.19.4. Strategic Outlook
14.4.20. COMPANY 20
14.4.20.1. Overview
14.4.20.2. Financials
14.4.20.3. Developments
14.4.20.4. Strategic Outlook